Table 4 Clinical, microbiological, and global response rates at various pre-defined efficacy timepoints throughout the study in the MITT population
MITT population | |||
|---|---|---|---|
Timepoint | Clinical response, % [n /N] (95% CI) | Microbiological response, % [n /N] (95% CI) | Global response, % [n /N] (95% CI) |
End of intravenous treatment | 81.0 [34/42] | 85.7 [36/42] | 78.6 [33/42] |
(65.9–91.4) | (71.5–94.6) | (63.2–89.7) | |
2 weeks after EOT | 83.9 [26/31] | 80.6 [25/31] | 75.0 [24/32] |
(66.3–94.5) | (62.5–92.5) | (56.6–88.5) | |
6 weeks after EOT | 56.7 [17/30] | 56.7 [17/30] | 54.8 [17/31] |
(37.4–74.5) | (37.4–74.5) | (36.0–72.7) | |
12 weeks after baseline | 54.8 [17/31] | 51.6 [16/31] | 50.0 [16/32] |
(36.0–72.7) | (33.1–69.8) | (31.9–68.1) | |